US 11,986,473 B2
Prevention and/or treatment of contrast-induced acute kidney injury
Anna Kazanchyan, Weston, CT (US); and Shalini Cornelio, Holmdel, NJ (US)
Assigned to Saghmos Therapeutics, Inc., Greenwich, CT (US)
Filed by Saghmos Therapeutics, Inc., Greenwich, CT (US)
Filed on Sep. 14, 2021, as Appl. No. 17/475,212.
Application 17/475,212 is a continuation of application No. 16/462,789, granted, now 11,123,345, issued on Sep. 21, 2021, previously published as PCT/US2017/062771, filed on Nov. 21, 2017.
Claims priority of provisional application 62/424,771, filed on Nov. 21, 2016.
Prior Publication US 2021/0401832 A1, Dec. 30, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/495 (2006.01); A61P 13/12 (2006.01)
CPC A61K 31/495 (2013.01) [A61P 13/12 (2018.01)] 13 Claims
 
1. A protocol to effect reduction of further impairment of kidney function in a subject who exhibits pre-existing impaired kidney function, which protocol comprises administering an effective amount of trimetazidine (TMZ) or pharmaceutically acceptable salt thereof to said subject prior to said subject undergoing a procedure that employs intravascular contrast media wherein said TMZ or pharmaceutically acceptable salt thereof is administered within 12 hours prior to start of said procedure and is continued for at least about 5 days after said procedure has been performed on said subject.